CNS Pharmaceuticals financials
$4.91−3.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$16.0M | -$14.9M | -$18.9M | -$15.3M | -$14.5M | -$9.5M | -$3.8M |
| Net income | -$15.9M | -$14.9M | -$18.9M | -$15.3M | -$14.5M | -$9.5M | -$3.9M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-35.75 | $-466.89 | $-150109.32 | $-16830000.00 | $-24750000.00 | $-25650000.00 | $-12600000.00 |
| EBITDA | -$16.0M | -$14.9M | -$18.9M | -$14.9M | -$14.5M | -$9.4M | -$3.7M |
| Operating cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M | -$7.3M | -$3.7M |
| Free cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M | -$7.3M | -$3.7M |
| Diluted shares | 0.4M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.2M | $6.5M | $548.7K | $10.1M | $5.0M | $14.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $328.0K | $326.1K | $300.8K | $410.0K | $387.8K | $439.3K |
| Total assets | $8.6M | $8.7M | $1.7M | $13.1M | $8.8M | $15.9M |
| Total liabilities | $4.1M | $2.5M | $6.1M | $4.9M | $2.6M | $1.9M |
| Shareholders' equity | $4.5M | $6.2M | -$4.4M | $8.1M | $6.2M | $13.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology